Literature DB >> 7720071

Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A.

I Richard1, O Broux, V Allamand, F Fougerousse, N Chiannilkulchai, N Bourg, L Brenguier, C Devaud, P Pasturaud, C Roudaut.   

Abstract

Limb-girdle muscular dystrophies (LGMDs) are a group of inherited diseases whose genetic etiology has yet to be elucidated. The autosomal recessive forms (LGMD2) constitute a genetically heterogeneous group with LGMD2A mapping to chromosome 15q15.1-q21.1. The gene encoding the muscle-specific calcium-activated neutral protease 3 (CANP3) large subunit is located in this region. This cysteine protease belongs to the family of intracellular calpains. Fifteen nonsense, splice site, frameshift, or missense calpain mutations cosegregate with the disease in LGMD2A families, six of which were found within La Réunion island patients. A digenic inheritance model is proposed to account for the unexpected presence of multiple independent mutations in this small inbred population. Finally, these results demonstrate an enzymatic rather than a structural protein defect causing a muscular dystrophy, a defect that may have regulatory consequences, perhaps in signal transduction.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7720071     DOI: 10.1016/0092-8674(95)90368-2

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  239 in total

Review 1.  Imaging of single DNA molecule: applications to high-resolution genomic studies.

Authors:  J Herrick; A Bensimon
Journal:  Chromosome Res       Date:  1999       Impact factor: 5.239

2.  Disruption of the murine calpain small subunit gene, Capn4: calpain is essential for embryonic development but not for cell growth and division.

Authors:  J S Arthur; J S Elce; C Hegadorn; K Williams; P A Greer
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

3.  The genexpress IMAGE knowledge base of the human muscle transcriptome: a resource of structural, functional, and positional candidate genes for muscle physiology and pathologies.

Authors:  G Piétu; E Eveno; B Soury-Segurens; N A Fayein; R Mariage-Samson; C Matingou; E Leroy; C Dechesne; S Krieger; W Ansorge; I Reguigne-Arnould; D Cox; A Dehejia; M H Polymeropoulos; M D Devignes; C Auffray
Journal:  Genome Res       Date:  1999-12       Impact factor: 9.043

4.  Characterization of the calcium-dependent proteolytic system in a mouse muscle cell line.

Authors:  Elise Dargelos; Stephane Dedieu; Catherine Moyen; Sylvie Poussard; Philippe Veschambre; Jean-Jacques Brustis; Patrick Cottin
Journal:  Mol Cell Biochem       Date:  2002-02       Impact factor: 3.396

5.  Molecular adaptations of neuromuscular disease-associated proteins in response to eccentric exercise in human skeletal muscle.

Authors:  L Féasson; D Stockholm; D Freyssenet; I Richard; S Duguez; J S Beckmann; C Denis
Journal:  J Physiol       Date:  2002-08-15       Impact factor: 5.182

6.  Capn5 is expressed in a subset of T cells and is dispensable for development.

Authors:  Tanna Franz; Lara Winckler; Thomas Boehm; T Neil Dear
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

Review 7.  Membrane Repair: Mechanisms and Pathophysiology.

Authors:  Sandra T Cooper; Paul L McNeil
Journal:  Physiol Rev       Date:  2015-10       Impact factor: 37.312

8.  Mdm muscular dystrophy: interactions with calpain 3 and a novel functional role for titin's N2A domain.

Authors:  Kimberly A Huebsch; Elena Kudryashova; Christine M Wooley; Roger B Sher; Kevin L Seburn; Melissa J Spencer; Gregory A Cox
Journal:  Hum Mol Genet       Date:  2005-08-22       Impact factor: 6.150

Review 9.  Emerging roles of calpain proteolytic systems in macrophage cholesterol handling.

Authors:  Takuro Miyazaki; Akira Miyazaki
Journal:  Cell Mol Life Sci       Date:  2017-04-21       Impact factor: 9.261

10.  Limitations of SLLVY-AMC in calpain and proteasome measurements.

Authors:  Christopher J Giguere; Rick G Schnellmann
Journal:  Biochem Biophys Res Commun       Date:  2008-05-05       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.